Cellular, Tissue, and Gene Therapies Advisory Committee; Notice of Meeting, 9766 [E7-3712]

Download as PDF 9766 Federal Register / Vol. 72, No. 42 / Monday, March 5, 2007 / Notices proposed participants and an indication of the approximate time requested to make their presentation on or before March 26, 2007. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by March 27, 2007. Persons attending FDA’s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Cathy Groupe at least 7 days in advance of the meeting. Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2). Dated: February 26, 2007. Randall W. Lutter, Associate Commissioner for Policy and Planning. [FR Doc. E7–3721 Filed 3–2–07; 8:45 am] BILLING CODE 4160–01–S DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. 2007N–0061] Cellular, Tissue, and Gene Therapies Advisory Committee; Notice of Meeting AGENCY: Food and Drug Administration, HHS. ACTION: Notice. erjones on PRODPC74 with NOTICES This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public. Name of Committee: Cellular, Tissue, and Gene Therapies Advisory Committee. General Function of the Committee: To provide advice and recommendations to the agency on FDA’s regulatory issues. Date and Time: The meeting will be held on March 29, 2007, from 8 a.m. to approximately 6:30 p.m. and on March 30, 2007 from 8 a.m. to approximately 3 p.m. VerDate Aug<31>2005 15:17 Mar 02, 2007 Jkt 211001 Address: Electronic comments should be submitted to https://www.fda.gov/ dockets/ecomments. Select Docket No. 2007N–0061, ‘‘Sipuleucel-T Dendreon,’’ and follow prompts to submit your statement. Written comments should be submitted to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, by close of business on March 22, 2007. All comments received will be posted without change, including any personal information provided. Comments received on or before March 22, 2007, will be provided to the committee before or at the meeting. Location: Hilton Washington DC North/Gaithersburg, 620 Perry Pkwy., Gaithersburg, MD, Grand Ballroom. Contact Person: Gail Dapolito or Rosanna L. Harvey, Center for Biologics Evaluation and Research (HFM–71), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301–827–1289, FAX: 301–827–0294, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 3014512389. Please call the Information Line for up-to-date information on this meeting. Agenda: On March 29, 2007, in open session, the committee will discuss Sipuleucel-T, Dendreon (BLA–STN 125197) indicated for the treatment of men with asymptomatic metastatic hormone refractory prostate cancer. The committee will also hear overviews of research programs in the Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research. On March 30, 2007, in open session, the committee will discuss the draft document entitled ‘‘Guidance for Industry: Minimally Manipulated, Unrelated, Allogeneic Placental/ Umbilical Cord Blood Intended for Hematopoietic Reconstitution in Patients with Hematological Malignancies.’’ For a copy of the draft guidance visit https://www.fda.gov/cber/ gdlns/cordbld.pdf. The committee will also discuss scientific issues regarding minimally manipulated, unrelated allogeneic peripheral blood stem cells. FDA intends to make background material available to the public no later than 1 business day before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA’s Web site after the meeting. Background material is available at https://www.fda.gov/ohrms/ dockets/ac/acmenu.htm, click on the PO 00000 Frm 00042 Fmt 4703 Sfmt 4703 year 2007 and scroll down to the appropriate advisory committee link. Procedure: On March 29, 2007, from 8 a.m. to approximately 5:30 p.m., and on March 30, 2007, from 8 a.m. to approximately 3 p.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before March 15, 2007. Oral presentations from the public will be scheduled between approximately 11:30 a.m. and 12:30 p.m. on March 29, 2007, and between 10 a.m. and 11 a.m. on March 30, 2007. Those desiring to make formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before March 7, 2007. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by March 8, 2007. Closed Committee Deliberations: On March 29, 2007, at approximately 5:30 p.m., the meeting will be closed to permit discussion where disclosure would constitute a clearly unwarranted invasion of personal privacy (5 U.S.C. 552b(c)(6)). The committee will discuss a report of intramural research programs in the Division of Cellular and Gene Therapies. Persons attending FDA’s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Gail Dapolito at least 7 days in advance of the meeting. Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2). Dated: February 26, 2007. Randall W. Lutter, Associate Commissioner for Policy and Planning. [FR Doc. E7–3712 Filed 3–2–07; 8:45 am] BILLING CODE 4160–01–S E:\FR\FM\05MRN1.SGM 05MRN1

Agencies

[Federal Register Volume 72, Number 42 (Monday, March 5, 2007)]
[Notices]
[Page 9766]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-3712]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 2007N-0061]


Cellular, Tissue, and Gene Therapies Advisory Committee; Notice 
of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). At least one 
portion of the meeting will be closed to the public.
    Name of Committee: Cellular, Tissue, and Gene Therapies Advisory 
Committee.
    General Function of the Committee: To provide advice and 
recommendations to the agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on March 29, 2007, from 8 
a.m. to approximately 6:30 p.m. and on March 30, 2007 from 8 a.m. to 
approximately 3 p.m.
    Address: Electronic comments should be submitted to https://
www.fda.gov/dockets/ecomments. Select Docket No. 2007N-0061, 
``Sipuleucel-T Dendreon,'' and follow prompts to submit your statement. 
Written comments should be submitted to the Division of Dockets 
Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, 
rm. 1061, Rockville, MD 20852, by close of business on March 22, 2007. 
All comments received will be posted without change, including any 
personal information provided. Comments received on or before March 22, 
2007, will be provided to the committee before or at the meeting.
    Location: Hilton Washington DC North/Gaithersburg, 620 Perry Pkwy., 
Gaithersburg, MD, Grand Ballroom.
    Contact Person: Gail Dapolito or Rosanna L. Harvey, Center for 
Biologics Evaluation and Research (HFM-71), Food and Drug 
Administration, 1401 Rockville Pike, Rockville, MD 20852, 301-827-1289, 
FAX: 301-827-0294, or FDA Advisory Committee Information Line, 1-800-
741-8138 (301-443-0572 in the Washington, DC area), code 3014512389. 
Please call the Information Line for up-to-date information on this 
meeting.
    Agenda: On March 29, 2007, in open session, the committee will 
discuss Sipuleucel-T, Dendreon (BLA-STN 125197) indicated for the 
treatment of men with asymptomatic metastatic hormone refractory 
prostate cancer. The committee will also hear overviews of research 
programs in the Division of Cellular and Gene Therapies, Center for 
Biologics Evaluation and Research. On March 30, 2007, in open session, 
the committee will discuss the draft document entitled ``Guidance for 
Industry: Minimally Manipulated, Unrelated, Allogeneic Placental/
Umbilical Cord Blood Intended for Hematopoietic Reconstitution in 
Patients with Hematological Malignancies.'' For a copy of the draft 
guidance visit https://www.fda.gov/cber/gdlns/cordbld.pdf. The committee 
will also discuss scientific issues regarding minimally manipulated, 
unrelated allogeneic peripheral blood stem cells.
    FDA intends to make background material available to the public no 
later than 1 business day before the meeting. If FDA is unable to post 
the background material on its Web site prior to the meeting, the 
background material will be made publicly available at the location of 
the advisory committee meeting, and the background material will be 
posted on FDA's Web site after the meeting. Background material is 
available at https://www.fda.gov/ohrms/dockets/ac/acmenu.htm, click on 
the year 2007 and scroll down to the appropriate advisory committee 
link.
    Procedure: On March 29, 2007, from 8 a.m. to approximately 5:30 
p.m., and on March 30, 2007, from 8 a.m. to approximately 3 p.m., the 
meeting is open to the public. Interested persons may present data, 
information, or views, orally or in writing, on issues pending before 
the committee. Written submissions may be made to the contact person on 
or before March 15, 2007. Oral presentations from the public will be 
scheduled between approximately 11:30 a.m. and 12:30 p.m. on March 29, 
2007, and between 10 a.m. and 11 a.m. on March 30, 2007. Those desiring 
to make formal oral presentations should notify the contact person and 
submit a brief statement of the general nature of the evidence or 
arguments they wish to present, the names and addresses of proposed 
participants, and an indication of the approximate time requested to 
make their presentation on or before March 7, 2007. Time allotted for 
each presentation may be limited. If the number of registrants 
requesting to speak is greater than can be reasonably accommodated 
during the scheduled open public hearing session, FDA may conduct a 
lottery to determine the speakers for the scheduled open public hearing 
session. The contact person will notify interested persons regarding 
their request to speak by March 8, 2007.
    Closed Committee Deliberations: On March 29, 2007, at approximately 
5:30 p.m., the meeting will be closed to permit discussion where 
disclosure would constitute a clearly unwarranted invasion of personal 
privacy (5 U.S.C. 552b(c)(6)). The committee will discuss a report of 
intramural research programs in the Division of Cellular and Gene 
Therapies.
    Persons attending FDA's advisory committee meetings are advised 
that the agency is not responsible for providing access to electrical 
outlets.
    FDA welcomes the attendance of the public at its advisory committee 
meetings and will make every effort to accommodate persons with 
physical disabilities or special needs. If you require special 
accommodations due to a disability, please contact Gail Dapolito at 
least 7 days in advance of the meeting.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: February 26, 2007.
Randall W. Lutter,
Associate Commissioner for Policy and Planning.
[FR Doc. E7-3712 Filed 3-2-07; 8:45 am]
BILLING CODE 4160-01-S

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.